Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04523246 · ClinicalTrials.gov registry record · Early Phase 1
Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents
A Early Phase 1 study, sponsored by University of Oklahoma.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 217
- Enrollment target
NCT04523246 is a Early Phase 1 study that has completed, run by University of Oklahoma. The registered enrollment target is 217 participants.
The verdict
NCT04523246, a Early Phase 1 study, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 217 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the effect of the Shingrix vaccine on your immune system and whether that has any effect on the body's ability to fight off other infections such as COVID-19. We hypothesize that: H1: Shingrix vaccination will elevate acute and trained immunity H2: For 6 months following the first injection, increased levels of acute and trained immunity is associated with less disease, including fewer hospitalizations and deaths associated with flu, pneumonia, and COVID-19.
Interventions
- DRUG Normal Saline
- BIOLOGICAL SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2023-05-19 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04523246
The ClinicalTrials.gov registry entry for NCT04523246 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal Saline is the first listed.
NCT04523246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04523246 about?
NCT04523246 is a clinical study titled "Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents". The purpose of this study is to measure the effect of the Shingrix vaccine on your immune system and whether that has any effect on the body's ability to fight off other infections such as COVID-19. We hypothesize that: H1: Shingrix vaccination will elevate acute and trained immunity H2: For 6 mon...
What is the current status of trial NCT04523246?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 217 participants. The study started on 2020-09-01. Estimated completion is 2023-05-19.
What interventions are being tested in trial NCT04523246?
The interventions under investigation include: Normal Saline (DRUG), SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04523246?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.